Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Stec, Maria [1 ]
Suleja, Agata [1 ]
Gondko, Daniel [1 ]
Kuczmik, Wiktoria [1 ]
Roman, Jakub [1 ]
Dziadosz, Dominika [2 ]
Szydlo, Krzysztof [2 ]
Mizia-Stec, Katarzyna [2 ]
机构
[1] Med Univ Silesia, Students Res Grp, Dept Cardiol 1, 47 Ziolowa St, PL-40635 Katowice, Poland
[2] Med Univ Silesia, Dept Cardiol 1, European Reference Network Heart Dis ERN GUARD HE, 47 Ziolowa St, PL-40635 Katowice, Poland
关键词
hypertrophic cardiomyopathy; atrial fibrillation; HCM-AF Risk Score; ATRIAL-FIBRILLATION; DIAGNOSIS; PROFILE;
D O I
10.3390/jcm12134484
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction
    Vaglio, JC
    Ommen, SR
    Nishimura, RA
    Gersh, BJ
    CIRCULATION, 2005, 112 (17) : U665 - U665
  • [22] Clinical characteristics and outcomes of patients with hypertrophic cardiomyopathy with latent obstruction
    Vaglio, Joseph C., Jr.
    Ommen, Steve R.
    Nishimura, Rick A.
    Tajik, A. Jamil
    Gersh, Bernard J.
    AMERICAN HEART JOURNAL, 2008, 156 (02) : 342 - 347
  • [23] Gender-Specific Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
    Lu, Dai-Yin
    Abraham, Maria R.
    CIRCULATION, 2018, 138
  • [24] Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy
    Lu, Dai-Yin
    Pozios, Iraklis
    Haileselassie, Bereketeab
    Ventoulis, Ioannis
    Liu, Hongyun
    Sorensen, Lars L.
    Canepa, Marco
    Phillip, Susan
    Abraham, M. Roselle
    Abraham, Theodore P.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (05):
  • [25] Clinical Characteristics and Outcomes in Patients With Apical and Nonapical Hypertrophic Cardiomyopathy
    Chen, Qin-Fen
    Zou, Jiahao
    Katsouras, Christos S.
    You, Shenban
    Zhou, Jian
    Ge, Hang-Bin
    Liu, Chenyang
    Zhou, Xi
    Ni, Chao
    Peng, Yangdi
    Hong, Chenlv
    Lin, Wei-Hong
    Zhou, Xiao-Dong
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (19):
  • [26] Association Between Depression and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
    Hu, Hui-Lin
    Chen, Hao
    Zhu, Chun-Yan
    Yue, Xin
    Wang, Hua-Wei
    Qian, Gang
    Zhai, Chang-Lin
    He, Chao-Jie
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (08):
  • [27] Clinical and Echocardiographic Predictors of Outcomes in Patients With Apical Hypertrophic Cardiomyopathy
    Moon, Jeonggeun
    Shim, Chi Young
    Ha, Jong-Won
    Cho, In Jeong
    Kang, Min Kyung
    Yang, Woo-In
    Jang, Yangsoo
    Chung, Namsik
    Cho, Seung-Yun
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (11): : 1614 - 1619
  • [28] Clinical Outcomes Following Primary Prevention Implantable Cardioverter Defibrillator (ICD) Implantation Among Older Patients With Hypertrophic Cardiomyopathy (HCM)
    Goldstein, Sarah A.
    Kennedy, Kevin
    Friedman, Daniel
    Al-Khatib, Sana M.
    Wang, Andrew
    CIRCULATION, 2022, 146
  • [29] Usefulness of a simple clinical score in identifying increased risk of transthyretin amyloid cardiomyopathy in older patients with unexplained hypertrophic cardiomyopathy
    Cappelli
    Garcia-Pavia, P.
    Elliott, P.
    Barriales-Villa, R.
    Piriou, N.
    Munteanu, C.
    Bahus, C.
    Keohane, D.
    Mallaina, P.
    Damy, T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 104 - 104
  • [30] RISK PROFILES AND CLINICAL OUTCOMES IN PATIENTS WITH NON-OBSTRUCTIVE, LABILE AND OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
    Lu, Dai-Yin
    Abraham, Theodore
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 832 - 832